Adverse event reporting to US Food and Drug Administration and risk evaluation and mitigation strategies

被引：0
|
作者：
Thompson, Deborah L. [1 ]
Welsh, Kerry [1 ]
Alimchandani, Meghna [1 ]
机构：
[1] US FDA, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave,Bldg 71, Silver Spring, MD 20993 USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
10.1016/j.ymthe.2023.03.003
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：918 / 918
页数：1
相关论文
共 50 条
  • [1] Analyzing the Effectiveness of the Food and Drug Administration Risk Evaluation and Mitigation Strategies Using the FDA Adverse Event Reporting System Database
    Chung, Stephanie
    Ohman-Strickland, Pamela
    Samet, Robin
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S204 - S204
  • [2] An Ecological Study on Consumer Adverse Event Reporting to the US Food and Drug Administration
    Munoz, M.
    Dal Pan, G.
    Xiao, H.
    Delcher, C.
    Wei, J.
    Kortepeter, C.
    Winterstein, A.
    [J]. DRUG SAFETY, 2018, 41 (11) : 1132 - 1132
  • [3] The safety of niacin in the US Food and Drug Administration Adverse Event Reporting database
    Alsheikh-Ali, Alawi A.
    Karas, Richard H.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8A): : 9B - 13B
  • [4] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Thomas J. Moore
    Richard L. Morrow
    Colin R. Dormuth
    Barbara Mintzes
    [J]. Pharmaceutical Medicine, 2020, 34 : 135 - 140
  • [5] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Moore, Thomas J.
    Morrow, Richard L.
    Dormuth, Colin R.
    Mintzes, Barbara
    [J]. PHARMACEUTICAL MEDICINE, 2020, 34 (02) : 135 - 140
  • [6] Adverse events reported to the US Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel
    Dores, Graca M.
    Jason, Christopher
    Niu, Manette T.
    Perez-Vilar, Silvia
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (09) : 1087 - 1100
  • [7] Use of Risk Evaluation and Mitigation Strategies by the US Food and Drug Administration, 2008-2019
    Guadamuz, Jenny S.
    Qato, Dima M.
    Alexander, G. Caleb
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (03): : 299 - 301
  • [8] Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Rahman, Md. Motiur
    Alatawi, Yasser
    Cheng, Ning
    Qian, Jingjing
    Plotkina, Annya V.
    Peissig, Peggy L.
    Berg, Richard L.
    Page, David
    Hansen, Richard A.
    [J]. EPILEPSY RESEARCH, 2017, 135 : 71 - 78
  • [9] Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Nango, Daisuke
    Sekizuka, Tuyoshi
    Goto, Makoto
    Echizen, Hirotoshi
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (04): : 341 - 344
  • [10] Comparisons of adverse event reporting for colistin versus polymyxin B using the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Cong Bang Truong
    Durham, Spencer H.
    Qian, Jingjing
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (05) : 603 - 609
12345